NBIX: Neurocrine Biosciences Inc. Stocks News on July 26, 2024

NBIX

Zacks

a day ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NBIX

Argus Research

3 days ago

NBIX: Lowering target price to $153.00

NBIX

MT Newswires

8 days ago

Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

NBIX

PR Newswire

8 days ago

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

NBIX

Argus Research

10 days ago

NBIX: Raising target price to $155.00

NBIX

Zacks

14 days ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

NBIX

PR Newswire

15 days ago

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

Top Medical Stocks to Buy for Growth & Performance

NBIX

Zacks

16 days ago

Top Medical Stocks to Buy for Growth & Performance

NBIX

Argus Research

17 days ago

NBIX: Raising target price to $150.00

NBIX

MT Newswires

17 days ago

RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating

NBIX

MT Newswires

24 days ago

Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing

NBIX

Argus Research

24 days ago

NBIX: Raising target price to $144.00

FDA grants priority review for Neurocrine’s crinecerfont NDAs

NBIX

Pharmaceutical Technology

25 days ago

FDA grants priority review for Neurocrine’s crinecerfont NDAs

NBIX

MT Newswires

25 days ago

Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

NBIX

PR Newswire

25 days ago

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

How Medicare drug price negotiations could hit pharma stocks

NBIX

Yahoo Finance Video

a month ago

How Medicare drug price negotiations could hit pharma stocks

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

NBIX

Investor's Business Daily

a month ago

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

NBIX

Simply Wall St.

a month ago

Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing

Neurocrine Biosciences to Participate at Investor Conferences in June

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences to Participate at Investor Conferences in June

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences Says CEO Kevin Gorman Retiring

Neurocrine Biosciences Announces CEO Succession Plan

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Announces CEO Succession Plan

NBIX

MT Newswires

2 months ago

UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers

NBIX

Investor's Business Daily

3 months ago

How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam

NBIX

Investor's Business Daily

3 months ago

Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

NBIX

MT Newswires

3 months ago

UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating

Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations

NBIX

Simply Wall St.

3 months ago

Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations

NBIX

GuruFocus.com

3 months ago

Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...

NBIX

GuruFocus.com

3 months ago

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

NBIX

Thomson Reuters StreetEvents

3 months ago

Q1 2024 Neurocrine Biosciences Inc Earnings Call

NBIX

GuruFocus.com

3 months ago

Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements

Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech

NBIX

Investor's Business Daily

3 months ago

Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech

NBIX

Zacks

3 months ago

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win

NBIX

Investor's Business Daily

3 months ago

No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell

NBIX

Zacks

3 months ago

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

NBIX

Associated Press Finance

3 months ago

Neurocrine: Q1 Earnings Snapshot

Neurocrine Biosciences Reports First Quarter 2024 Financial Results

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Reports First Quarter 2024 Financial Results

NBIX

Reuters

3 months ago

UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval

NBIX

MT Newswires

3 months ago

Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours

NBIX

Reuters

3 months ago

FDA approves Neurocrine Biosciences' Huntington's disease drug

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules

NBIX

Zacks

3 months ago

Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics

NBIX

Zacks

3 months ago

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $147.00

Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?

NBIX

Investor's Business Daily

3 months ago

Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?

No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win

NBIX

Investor's Business Daily

3 months ago

No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win

Neurocrine scores surprise win with depression drug

NBIX

BioPharma Dive

3 months ago

Neurocrine scores surprise win with depression drug

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

NBIX

Insider Monkey

3 months ago

10 Best Performing Biotech ETFs in 2024

NBIX

GlobeNewswire

3 months ago

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

NBIX

Insider Monkey

4 months ago

11 Best Biotech ETFs To Buy

NBIX

Simply Wall St.

4 months ago

Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Performance Tethered To Its Attractive Financial Prospects?

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

NBIX

Investor's Business Daily

4 months ago

S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

Dow Jones Futures: Apple Sour, But These 11 Stocks Flash Buy Signals; FedEx Soars

NBIX

Investor's Business Daily

4 months ago

Dow Jones Futures: Apple Sour, But These 11 Stocks Flash Buy Signals; FedEx Soars

AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base

NBIX

Investor's Business Daily

4 months ago

AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base

Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares

NBIX

GuruFocus.com

4 months ago

Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares

NBIX

GuruFocus.com

4 months ago

Director Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX)

Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders

NBIX

GuruFocus.com

4 months ago

Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders

NBIX

GuruFocus.com

4 months ago

Director Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX)

Neurocrine Biosciences to Participate at Virtual Investor Conferences in March

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences to Participate at Virtual Investor Conferences in March

The $1 Billion Opportunity Driving IBD Stock Of The Day Neurocrine Higher

NBIX

Investor's Business Daily

5 months ago

The $1 Billion Opportunity Driving IBD Stock Of The Day Neurocrine Higher

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success

NBIX

InvestorPlace

5 months ago

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success

Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares

NBIX

GuruFocus.com

5 months ago

Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares

Neurocrine Biosciences to Participate at Investor Conferences in March

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences to Participate at Investor Conferences in March

Director Richard Pops Sells 15,000 Shares of Neurocrine Biosciences Inc

NBIX

GuruFocus.com

5 months ago

Director Richard Pops Sells 15,000 Shares of Neurocrine Biosciences Inc

11 Best Small-Cap Growth Stocks to Invest In

NBIX

Insider Monkey

5 months ago

11 Best Small-Cap Growth Stocks to Invest In

Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares

NBIX

GuruFocus.com

5 months ago

Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares

Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks

NBIX

Insider Monkey

6 months ago

Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks

NBIX

GuruFocus.com

6 months ago

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

Neurocrine Biosciences Full Year 2023 Earnings: EPS Beats Expectations

NBIX

Simply Wall St.

6 months ago

Neurocrine Biosciences Full Year 2023 Earnings: EPS Beats Expectations

NBIX

GuruFocus.com

6 months ago

Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares

NBIX

Insider Monkey

6 months ago

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript

NBIX

Thomson Reuters StreetEvents

6 months ago

Q4 2023 Neurocrine Biosciences Inc Earnings Call

NBIX

Zacks

6 months ago

Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

NBIX

GuruFocus.com

6 months ago

Neurocrine Biosciences Inc (NBIX) Reports Strong Growth in INGREZZA Sales for Q4 and Full Year 2023

NBIX

Associated Press Finance

6 months ago

Neurocrine: Q4 Earnings Snapshot

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024

NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024

NBIX

Zacks

6 months ago

Ahead of Neurocrine (NBIX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Cboe Global Markets, Inc. (CBOE:CBOE) Q4 2023 Earnings Call Transcript

NBIX

Insider Monkey

6 months ago

Cboe Global Markets, Inc. (CBOE:CBOE) Q4 2023 Earnings Call Transcript

Neurocrine Biosciences Inc CFO Matt Abernethy Sells Company Shares

NBIX

GuruFocus.com

6 months ago

Latest Neurocrine Biosciences Inc. (NBIX) News on July 26, 2024

Share on Social Networks: